BSE .
Panacea Biotec's board approved standalone and consolidated unaudited financial results for Q2 and H1 FY2025, reviewed by auditors.
Total income for H1 FY2025 reached ₹21,162 lakh standalone and ₹31,990 lakh consolidated, with net profit after tax at ₹2,234 lakh and ₹1,005 lakh respectively.